Management of Decompensated Alcoholic Liver Disease
Core Management Principles
- Complete alcohol abstinence is essential for patients with decompensated alcoholic liver disease to reduce the risk of complications and mortality, as recommended by the European Association for the Study of the Liver 1, 2
- The American Association for the Study of Liver Diseases recommends pharmacologic options to support abstinence, including Baclofen, which is the only anti-craving medication formally tested and proven safe in patients with advanced liver disease 3
- Brief interventions using the FRAMES model (Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy) should be implemented to encourage abstinence, as suggested by the Clinical and Molecular Hepatology guidelines 4, 6
Management of Complications
- The European Association for the Study of the Liver recommends managing ascites with sodium restriction, diuretics, and paracentesis according to standard cirrhosis guidelines, with approximately 20% risk in the first year 1, 2, 7
- Hepatic encephalopathy is associated with the highest mortality among complications of decompensated cirrhosis, and should be treated according to standard guidelines with lactulose and rifaximin, as recommended by the American Association for the Study of Liver Diseases 1, 7
- Patients with alcoholic cirrhosis are particularly prone to bacterial infections, and should be monitored closely for signs of infection, as suggested by the Journal of Hepatology guidelines 2, 7
Prognostic Assessment
- The Model for End-Stage Liver Disease (MELD) score should be used to establish prognosis and prioritize for liver transplantation, as recommended by the American Association for the Study of Liver Diseases 7
- The development of hepatic encephalopathy carries the worst prognosis among complications, with one and five-year mortality risks of approximately 30% and 60%, respectively, in alcoholic cirrhosis 7
Screening for Other Complications
- Patients with alcoholic cirrhosis should be screened for hepatocellular carcinoma (HCC) as recommended for any patient with cirrhosis, with annual incidence of 2.6% in alcoholic cirrhosis, as suggested by the European Association for the Study of the Liver 1, 5
- Evaluation for alcohol-induced damage to other organs, including the heart, kidneys, nervous system, and pancreas, should be performed, as recommended by the American Association for the Study of Liver Diseases 2, 7